이식형 경골 신경조절 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종사용별, 지역별 및 부문별 예측(2026-2033년)

Implantable Tibial Neuromodulation Market Summary

The global implantable tibial neuromodulation market size was estimated at USD 54.46 million in 2025 and is projected to reach USD 87.37 million by 2033, growing at a CAGR of 6.88% from 2026 to 2033. The market is driven by the rising prevalence of conditions such as overactive bladder and urinary incontinence, particularly among the aging population.

The increasing preference for minimally invasive, long-term treatment solutions over conventional therapies, along with technological advancements in neuromodulation devices, is further supporting market growth. In addition, growing awareness and improved access to urological care are accelerating adoption rates globally.

The increasing prevalence of bladder disorders such as overactive bladder and urinary incontinence is a key driver of the implantable tibial neuromodulation industry, as these conditions require effective long-term management solutions. As patient numbers rise globally, demand for minimally invasive, durable therapies is increasing. This trend is accelerating the adoption of implantable neuromodulation devices that offer improved symptom control and quality of life. According to the National Center for Biotechnology Information, in August 2024, the prevalence of urinary incontinence in men was approximately half that observed in women. It was estimated that 11% to 34% of older men experience urinary incontinence, with 2% to 11% reporting daily symptoms, while the risk is notably higher among individuals undergoing prostate surgery.

Global Implantable Tibial Neuromodulation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global implantable tibial neuromodulation market report based on product, indication, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Lead-Based Tibial Implants
• Leadless Tibial Implants
• Hybrid/Accessory Systems
• Indication Outlook (Revenue, USD Million; 2021 - 2033)
• Overactive Bladder (OAB)
• Urge Urinary Incontinence (UUI)
• Fecal Incontinence (FI)
• Chronic Pelvic Pain/Interstitial Cystitis
• Neurogenic Bladder Disorders
• End Use Outlook (Revenue, USD Million; 2021 - 2033)
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Urology & Urogynecology Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Indication
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Implantable Tibial Neuromodulation Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of urological disorders
    • 3.2.1.2. Growing preference for minimally invasive therapies
    • 3.2.1.3. Advancements in neuromodulation technology
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of implantable devices and procedures
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Expansion in emerging markets
    • 3.2.3.2. Strategic partnerships and collaborations
    • 3.2.3.3. Pipeline expansion into broader indications
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Complexity of implantation procedures
    • 3.2.4.2. Patient acceptance and awareness issues
• 3.3. Implantable Tibial Neuromodulation Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Implantable Tibial Neuromodulation Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Implantable Tibial Neuromodulation Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Implantable Tibial Neuromodulation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Leadless Tibial Implants
  • 4.4.1. Leadless tibial implants market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Lead-Based Tibial Implants
  • 4.5.1. Lead-based tibial implants market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Hybrid/Accessory Systems
  • 4.6.1. Hybrid/accessory systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Implantable Tibial Neuromodulation Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Implantable Tibial Neuromodulation Market: Indication Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Implantable Tibial Neuromodulation Market Size & Trend Analysis, by Indication 2021 to 2033 (USD Million)
• 5.4. Overactive Bladder (OAB)
  • 5.4.1. Overactive bladder (OAB) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Urge Urinary Incontinence (UUI)
  • 5.5.1. Urge urinary incontinence (UUI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Fecal Incontinence (FI)
  • 5.6.1. Fecal incontinence (FI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Chronic Pelvic Pain/Interstitial Cystitis
  • 5.7.1. Chronic pelvic pain/interstitial cystitis market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Neurogenic Bladder Disorders
  • 5.8.1. Neurogenic bladder disorders market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Implantable Tibial Neuromodulation Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Implantable Tibial Neuromodulation Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Implantable Tibial Neuromodulation Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Ambulatory Surgical Centers (ASCs)
  • 6.5.1. Ambulatory surgical centers (ASCs) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Specialty Urology & Urogynecology Clinics
  • 6.6.1. Specialty urology & urogynecology clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Implantable Tibial Neuromodulation Market: Regional Estimates & Trend Analysis by Product, Indication and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait implantable tibial neuromodulation market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. Valencia Technologies (Boston Scientific Corporation)
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. BlueWind Medical
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Medtronic
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives